Protective effect of liraglutide on the myocardium of type 2 diabetic rats by inhibiting polyadenosine diphosphate-ribose polymerase-1

Figure 1 Weekly body weight and fasting blood glucose trend of rats in each group after liraglutide intervention. A: Weekly body weight; B: Fasting blood glucose trend. N: Normal control; M: Model; HL: High-dose liraglutide; LL: Low-dose liraglutide; FBG: Fasting blood glucose.

Figure 2 Comparison of heart weight index in each group. Compared with group N, ^aP < 0.05; compared with group M, ^bP < 0.05; compared with group L, ^cP < 0.05. HWI: Heart weight index; N: Normal control; M: Model; HL: High-dose liraglutide; LL: Low-dose liraglutide.

Figure 3 Haematoxylin and eosin staining of the hearts of rats in each group (400×). A: Normal control group; B: Model group; C: Low-dose liraglutide group; D: High-dose liraglutide group.

Figure 4 Comparison of immunohistochemistry of myocardial tissue in each group. A-D: Polyadenosine diphosphate-ribose polymerase-1 (PARP-1) expression in heart tissue of rats in normal control group (A), model group (B), low-dose liraglutide group (C), and high-dose liraglutide group (D); E: Comparison of PARP-1 positive expression in heart tissue of rats in each group. Compared with group N, ^aP < 0.05; compared with group M, ^bP < 0.05; compared with group L, ^cP < 0.05. PARP-1: Polyadenosine diphosphate-ribose polymerase-1; N: Normal control; M: Model; HL: High-dose liraglutide; LL: Low-dose liraglutide.